Primary aldosterone excess or hyperaldosteronism is an important cause of hypertension which, when associated with an aldosterone secreting adenoma, is amenable to surgical cure. The biochemical hallmarks of the condition are a relative excess of aldosterone production with suppression of plasma levels of renin (a proxy for angiotensin II, the major trophic substance regulating aldosterone secretion). This combination of a high aldosterone and a low renin is however more commonly associated with 'nodular hyperplasia' of the adrenal glands, a condition not improved by surgery and variably responsive to the effects of the mineralocorticoid antagonist, spironolactone. Until recently the prevalence of either form of secondary hypertension has been thought to be low such that few clinicians 'hunted' for it in the absence of hypokalaemia (the traditional clue for the syndrome). This view has been challenged, firstly by the realisation that no more than 50% of such patients will have a low plasma potassium and secondly by the assumption that a 'normal' plasma Keywords: primary aldosterone excess; Conn's syndrome; low-renin; hyperaldosteronism; aldosterone/renin ratio Introduction I have lived and worked throughout a quarter of a century where clinical hypertension research has been both productive and exciting. This has been no more so that in the area of mineralocorticoid hypertension.
Introduction
I have lived and worked throughout a quarter of a century where clinical hypertension research has been both productive and exciting. This has been no more so that in the area of mineralocorticoid hypertension.
Fashions change however and I well remember starting out in hypertension research in a unit where every patient had a full assessment of the reninangiotensin-aldosterone system. This was only partly for research purposes as there was a genuine belief that this system was intimately concerned in the pathogenesis of high blood pressure. As the years have passed my own philosophical approach to the hypertensive patient has changed. I no longer believe that most hypertensive patients harbour a single causative factor, the removal of which will cure hypertension. I have moved from a time when we investigated everybody 1 to one where I investigate few and I am not persuaded that this is the wrong approach.
Background
On 29 October 1954 Jerome Conn gave his presidential address at the 27th Annual Meeting of the Central Society for Clinical Research in the United States of America. 2 He described a patient with hypertension who was cured by the removal of an adrenal tumour. I was privileged to work in the institution where he investigated the index patient, a middle-aged female, for many weeks before finally persuading a surgeon that she must have an adrenal tumour and that he (the surgeon) had but to find it. It is worth remembering that Conn had none of the benefits of the modern clinician and indeed, at that time, aldosterone had not even been discovered. It was not long before electrocortin, as it was called by the Taits in London, became 'aldosterone' and it was clear that what Conn had described was a benign aldosterone-producing adenoma of the adrenal gland. This condition has since been eponymously named, Conn's syndrome. Renin had been known about for over 50 years and as assays became available for the measurement of both renin activity in plasma and aldosterone in urine, and subsequently plasma, it became clear that Conn's syndrome of aldosterone excess resulted in sodium retention and suppression of renin. The hallmark of Conn's syndrome was high aldosterone production with a suppressed renin. Initially all patients investigated had hypokalaemia but it became apparent that not all patients with low renin aldosterone excess had an adrenal adenoma. 3 In early series it seemed clear that about a quarter of such patients had what came to be called idiopathic hyperplasia or pseudo hyperaldosteronism. These patients did not have a discreet tumour but had nodular adrenal glands. 4 Some nodules could be large being indistinguishable from true tumours in a variety of imaging techniques. 5 While the removal of an aldosterone producing adrenal adenoma resulted in cure of hypertension in at least 70% of cases, surgery for nodular hyperplasia did not. 6 There were even examples in the literature of patients who had both adrenal glands removed but who remained hypertensive following replacement therapy. This is not surprising if it is appreciated that the nodules from hyperplastic glands do not make aldosterone; whereas of course tumours do. 7 This observation threw into question the whole notion of what so-called primary aldosteronism meant. The optimism of the 1960s where it was genuinely believed by some that up to 20% of patients with hypertension might have primary aldosteronism gradually subsided throughout the 1970s and most of the 1980s to a belief that primary aldosterone excess was a rare cause of hypertension. Most textbooks and recent reviews now give it a prevalence rate of probably less than 1% of the hypertensive population. 8 
Pathophysiology
The measurement of plasma renin was always more readily available to clinicians than was the measurement of aldosterone and in the search for aldosterone excess it was found that a significant proportion of patients (who otherwise had essential hypertension) had a low or suppressed plasma renin activity. While working at the MRC BP unit in Glasgow 25 years ago, I showed that plasma renin levels, just like blood pressure itself, were normally distributed in hypertensive patients and therefore any subdivision of hypertension based on the renin level was as arbitrary as the definition of hypertension itself. 9 Nonetheless, there was a flurry of literature in the 1970s describing the condition of low renin hypertension. These patients did not have aldosterone excess but because low renin was a hallmark of mineralocorticoid effect a search ensued for other mineralocorticoids. Isolated case reports appeared identifying this or that adrenal steroid that might be the cause of hypertension in such patients. In retrospect it is clear of course that a relative aldosterone excess (for a given level of renin) was present in those patients with low renin hypertension. The absence of a suppressed aldosterone level was against a role for an alternative mineralocorticoid (see Padfield et al 9 ) . Through the 1970s it became clear to us in Glasgow that the differences between so-called idiopathic hyperplasia and low renin hypertension were quantitative rather than qualitative. Seminal studies performed around that time showed quite clearly that:
• Patients with true Conn's syndrome had plasma aldosterone levels that were insensitive to changes in circulating angiotensin II (induced by assumption of the erect posture or by infusion of the peptide itself).
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• Patients with the idiopathic hyperplastic variety of primary aldosteronism had an enhanced aldosterone response to such manoeuvres. 11, 12 Idiopathic hyperplasia of the adrenal glands associated with aldosterone excess was not primary aldosteronism at all but some form of secondary aldosteronism whereby the adrenal gland was exquisitely sensitive to small changes in circulating angiotension II. The coup de grace for those who believed in qualitative differences was the observation that when patients with low renin hypertension (a low circulating renin with a normal aldosterone) were infused with angiotensin II they behaved exactly as did the hyperplastic patients with an exaggerated aldosterone response.
We wrote in several papers around the middle 1970s that idiopathic hyperaldosteronism and low renin hypertension were simply a continuum in the spectrum of essential hypertension (see Padfield et al 4 , Davies et al 10 ). There was much other circumstantial evidence to support this view.
• In patients with tumerous Conn's syndrome a plot of circulating renin or angiotensin II against aldosterone produced a negative correlation (aldosterone induced sodium retention suppressing renin) whereas in those with the hyperplastic form of the disease the relationship was positive (see Davies et al 10 ) . This is exactly what would be expected if the aldosterone was high as a result of angiotensin II.
• Patients with Conn's syndrome had other evidence of mineralocorticoid excess in that exchangeable sodium was always elevated; it was not in the hyperplastic variety being on a par with those patients with low renin hypertension.

Clinical consequences
Arguing as a purist for a particular disease entity, or lack of it, is less important than appropriate treat-ment for patients. Although it had become clear that surgical therapy was not an option for patients with hyperplastic adrenal glands there was still the hope that they might respond to the aldosterone antagonist spironolactone. The response to spironolactone had been shown to be a good predictor of the response to adrenal surgery in those patients with an adrenal tumour. 13 Patients with the hyperplastic form of the disease did have good blood pressure responses to spironolactone (300 mg or 400 mg per day).
14 Spironolactone was also used for low renin hypertension and although equally successful, was no better than conventional thiazide diuretics. 15 I know of no studies to address the question as to whether thiazides would be equally efficacious in patients with hyperplastic aldosterone excess.
The diagnosis of 'primary aldosteronism'
Diagnosing aldosterone excess was always difficult because most of the drugs that were used in the treatment of hypertension had an effect on the renin angiotension aldosterone axis. Drugs either stimulated (diuretics, ACE inhibitors) or suppressed renin (beta-blockers) and in the early days we always took patients off their drugs, changing treatment to bethanidine, a drug known not to impact on the renin angiotension system. This was time consuming (it took several weeks for the effect of drugs on the renin angiotension system to wear off), uncomfortable for the patients (bethanidine was not a good drug) and the pick-up rate after investigation was of course low. The fact that there are no drugs that simultaneously suppress renin while stimulating aldosterone led to arguments that the ratio of aldosterone to renin might be a good predictor of the state of primary aldosterone excess. It was postulated as early as 1981 that use of the ratio was a good way to diagnose patients with primary aldosteronism with an adrenal tumour. 16 Since that original paper others have used the ratio to diagnose all forms of low-renin aldosterone excess. 17 Such a position ignores the fact that the ratio of aldosterone to renin is increased in hypertensive patients compared with normal subjects. 10 In addition, the ratio is affected predominantly by the level of PRA rather than aldosterone such that, almost by definition, low renin hypertension is reclassified as hyperaldosteronism. As already argued the differentiation of low renin hypertension from idiopathic hyperplasia as a cause of aldosterone excess is probably quantitative rather than qualitative. The only important therapeutic decision therefore would be whether such a test would identify patients with true Conn's syndrome?
Hyperaldosteronism-common enough to hunt?
Richard Gordon in Brisbane has spent much of his academic life researching into mineralocorticoid Journal of Human Hypertension hypertension and over the years he has developed complicated protocols for the investigation of patients with hypertension. Initially he only investigated patients with hypokalaemia for the presence of aldosterone excess but as it became clear that 20-50% of patients with aldosterone excess did not present with hypokalaemia he investigated more widely, including patients with resistant hypertension. His current claim is that by doing this (using the aldosterone: renin ratio as the screening test) he believes that primary aldosteronism has a prevalence of around 12% amongst patients with hypertension. 18 Most patients identified do not have surgically curable disease and it is difficult to be clear from his published papers how often he discovers an aldosterone producing adenoma? The Brisbane group have recently changed their stance on how the test should be performed and they now suggest that drug therapy is withdrawn before testing. 19 This is no longer a simple process and it is my contention that most of the patients being identified by this screening test have what I would have called low renin hypertension or idiopathic hyperplasia depending where the cut-off point is drawn. The same argument applies to recent studies within Tayside where a similar prevalence of primary aldosterone excess is claimed 20 (again evidence from surgical cure is lacking).
Pragmatic perspectives
It would truly be foolish to argue against using the aldosterone renin ratio as a screening test if it indeed led to better targeted therapy for a significant proportion of hypertensive patients and I am prepared to eat my words if this is shown to be the case. A recent publication from Tayside (from the group who suggested a prevalence of aldosterone excess of 13%) has suggested that spironolactone is successful in treating blood pressure in these patients where other drugs have failed. 21 A claim, which if true, would refute all my arguments above. The study however was totally uncontrolled and it is distinctly possible that within the careful observation of a trial situation patients were more compliant than they might otherwise have been. The answer to this question would only be resolved by a randomised control trial of spironolactone or other aldosterone antagonists against some other form of therapy.
It is not a simple matter to confirm or refute a diagnosis of primary hyperaldosteronism and until we have better data on the outcomes of an expensive process we should leave well alone!
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Conclusions
When we first wrote in 1981 in the Lancet that the term idiopathic hyperaldosteronism was a myth (see Padfield et al 4 ) , we suggested that there is something within the human psyche that needs to classify. It is inherent in our whole handling of the topic of blood pressure in that we need cut-off points to define hypertension from normotension; even though we know that blood pressure is a continuum in the population. The same is true regarding aldosterone levels in plasma. Even if aldosterone is related to the simultaneous renin level there will not be daylight between normal and abnormal and unless or until there is clear evidence that a significant proportion of patients are identified who will be managed differently it is hard to justify advocating the widespread use of this test even though it is relatively simple. I still hold to the quotation we used in the Lancet in 1981 as follows:
'The tendency has always been strong to believe that whatever receives a name must be an entity or being, having an independent existence of its own; and if no real entity answering to the name could be found man did not for that reason suppose that none existed but imagined that it was something peculiarly abstruse and mysterious, too high to be an object of sense.' J Stewart Mill (1869) 23 
